CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Asfotase alfa

Last Updated: July 20, 2015
Result type: Reports
Project Number: SR0443-000
Product Line: Reimbursement Review

Generic Name: Asfotase alfa

Brand Name: Strensiq

Manufacturer: Alexion Pharmaceuticals Canada

Therapeutic Area: Hypophosphatasia, pediatric-onset

Indications: Hypophosphatasia, pediatric-onset

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: March 23, 2016

Recommendation Type: List with criteria/condition